ITHANET

A new article was added in IthaPedia under the Category Tag "Educational resources". The aim of this section is to create an online repository of educational articles, written by experts on the corresponding topic, that will be useful for both patients and scientists. The new article was written by Ersi Voskaridou, Dimitrios Christoulas and Evangelos Terpos and is entitled "Thalassaemia induced osteoporosis".

 

The ITHANET Team would like to thank the authors for their valuable contribution.

 

More information: IthaPedia

cvbfeu

The purpose of this study is to assess the non-inferiority of DFP compared to DFX (deferasirox)in paediatric patients affected by hereditary haemoglobinopathies requiring chronic transfusions and chelation. Non inferiority will be established in terms of percentage of patients successfully chelated, as assessed by serum ferritin levels (in all patients) and cardiac MRI T2* (in patients above 10 years of age able to have an MRI scan without sedation).

 

More information: clinicaltrials.gov, ITHANET Clinical Trials

euThe European Commission has today, on Rare Disease Day 2013, announced €144 million of new funding for 26 research projects on rare diseases. The projects will help improve the lives of some of the 30 million Europeans suffering from a rare disease. The selected projects bring together over 300 participants from 29 countries in Europe and beyond, including teams from leading academic institutions, SMEs and patients' groups. The goal is to pool resources and work beyond borders, to get a better understanding of rare diseases and find adequate treatments.

One of the projects, entitled THALAMOSS (THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia), aims to develop universal sets of markers and techniques for stratification of β-thalassaemia patients into treatment subgroups for (a) onset and frequency of blood transfusions, (b) choice of iron chelation, (c) induction of fetal hemoglobin, (d) prospective efficacy of gene-therapy.

To view all the projects, please see the MEMO/13/148 and visit the website. For more information, please see the official press release.

vanderbilt uni

Given large absolute numbers of individuals with sickle cell disease in Nigeria, hydroxyurea therapy for all individuals with sickle cell disease may not be initially feasible; however, a targeted strategy of hydroxyurea use for primary prevention of strokes is an alternative to the standard therapy (observation) for high-risk individuals. The investigators therefore propose a feasibility study, Sickle Cell Disease - Stroke Prevention in Nigeria (SPIN) Trial, to determine whether hydroxyurea can be used for primary prevention of strokes in Nigerian children with sickle cell anemia.

 

More information: clinicaltrials.gov, ITHANET Clinical Trials

Duke logo

The majority of school-age children with sickle cell disease (SCD) experience neurocognitive deficits, even in the absence of stroke. In particular, deficits in attention and working memory have emerged as two of the most common neurocognitive sequelae of SCD. Thus, the goal of the present proposal is to address feasibility and compliance of a novel computerized cognitive training program, Cogmed. Pilot data will also be collected to establish preliminary efficacy.

 

More information: clinicaltrials.gov, ITHANET Clinical Trials